Attovia Therapeutics
Attovia, a California-based medical firm, develops biotherapeutics for immune diseases and oncology using a novel nanobody platform.
- 44
- Company
- San Carlos, CA, USUnited States
Attovia, a California-based medical firm, develops biotherapeutics for immune diseases and oncology using a novel nanobody platform.
attovia.comCrawled Oct 15, 2026
Attovia's pipeline leverages ATTOBOY technology to develop medicines with better efficacy where existing treatments fall short.
The company works together, celebrates its successes, and learns together.
The company is a team of drug development leaders that develops therapeutics using Attobody technology.
The page provides contact options for general and media inquiries, collaborations, and career opportunities.
Harnessing ATTOBODY technology to bring treatments to patients where none exist or where current solutions fall short.
Attovia Therapeutics, Inc.’s cookie notice describes its use of cookies and other tracking technologies, privacy, and how it may use collected information.
Attovia Therapeutics, Inc. says it collects, uses, and shares personal information and processes it in accordance with applicable national, provincial/state, and local laws.
The website terms govern users’ use of the website and its pages.
Attovia Therapeutics demonstrates ATTO-1310’s rapid relief in chronic itching trials across two patient groups. The company upsizes its IPO to extend cash reserves through 2030, though reported losses rise. Follow-up studies for ATTO-1310 are underway.
Sep 2026Stock TitanNews article
Attovia Therapeutics, a clinical-stage biopharmaceutical company backed by Qiming Venture Partners, lists on Nasdaq at $17 per share and opens at $21. The company achieves a market capitalization of approximately $904 million. Attovia focuses on developing immune-mediated disease therapeutics.
Aug 2026Yahoo FinanceNews article
Attovia Therapeutics Inc. priced its IPO at $17 per share, raising $289 million after upsizing the offering to 17 million shares. The company’s shares closed at $21.90 on their first day of trading, marking a 28.8% increase from the offering price.
Aug 2026bioworld.comNews article
Attovia Therapeutics prices an upsized initial public offering (IPO) to raise capital. The clinical-stage biopharmaceutical company focuses on developing novel therapies. The move follows earlier preparations for a Nasdaq-listed debut under the ticker **ATTO**.
Aug 2026news.futunn.comNews article